The above results show that the incidence of co-mutation of TP53 and ARID1A in patients with r/r MB-NHL was significantly higher than that in patients with initial remission (TP53-mut&ARID1A-mut: n = 16, TP53-mut&ARID1A-wt: n = 20, TP53-wt&ARID1A-mut: n = 1, TP53-wt&ARID1A-wt: n = 11, P = 0.018, Fig. 5a). Here, ARID1A is linked to non-Hodgkin lymphoma.